CA3172205A1 - Farnesoid x receptor agonists for the treatment of disease - Google Patents
Farnesoid x receptor agonists for the treatment of disease Download PDFInfo
- Publication number
- CA3172205A1 CA3172205A1 CA3172205A CA3172205A CA3172205A1 CA 3172205 A1 CA3172205 A1 CA 3172205A1 CA 3172205 A CA3172205 A CA 3172205A CA 3172205 A CA3172205 A CA 3172205A CA 3172205 A1 CA3172205 A1 CA 3172205A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- disease
- acceptable salt
- pharmaceutically acceptable
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062991292P | 2020-03-18 | 2020-03-18 | |
| US62/991,292 | 2020-03-18 | ||
| US202063069667P | 2020-08-24 | 2020-08-24 | |
| US63/069,667 | 2020-08-24 | ||
| US202163140735P | 2021-01-22 | 2021-01-22 | |
| US63/140,735 | 2021-01-22 | ||
| PCT/US2021/022786 WO2021188688A1 (en) | 2020-03-18 | 2021-03-17 | Farnesoid x receptor agonists for the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3172205A1 true CA3172205A1 (en) | 2021-09-23 |
Family
ID=77771857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3172205A Pending CA3172205A1 (en) | 2020-03-18 | 2021-03-17 | Farnesoid x receptor agonists for the treatment of disease |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230131804A1 (enExample) |
| EP (1) | EP4121048A4 (enExample) |
| JP (1) | JP7851856B2 (enExample) |
| KR (1) | KR20220154801A (enExample) |
| CN (4) | CN120732855A (enExample) |
| AU (1) | AU2021240001A1 (enExample) |
| BR (1) | BR112022018651A2 (enExample) |
| CA (1) | CA3172205A1 (enExample) |
| IL (1) | IL296539A (enExample) |
| MX (1) | MX2022011579A (enExample) |
| TW (1) | TWI895384B (enExample) |
| WO (1) | WO2021188688A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3852748B1 (en) | 2018-09-18 | 2025-09-03 | Eli Lilly and Company | Farnesoid x receptor agonists and uses thereof |
| CN120227340A (zh) | 2020-03-18 | 2025-07-01 | 伊莱利利公司 | 法尼醇x受体激动剂的制剂 |
| JP7664278B2 (ja) * | 2020-03-18 | 2025-04-17 | オルガノボ，インク． | ファルネソイドｘ受容体アゴニストの結晶質形態 |
| CN117018000B (zh) * | 2023-08-29 | 2025-01-28 | 东莞市东南部中心医院(东莞市东南部中医医疗服务中心) | 4-胆甾烯-3-酮在制备预防或治疗炎症性肠病药物中的应用 |
| WO2026149323A1 (en) * | 2025-01-07 | 2026-07-16 | Shenzhen Hightide Biopharmaceutical Ltd. | Compositions and methods of using mitochondrial uncouplers and glp-1 receptor agonists |
| CN120837611B (zh) * | 2025-09-22 | 2025-12-16 | 吉林大学 | 一种经鼻给药的司美格鲁肽制剂及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2545964A1 (en) * | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| AU2016233579A1 (en) * | 2015-03-13 | 2017-10-12 | Salk Institute For Biological Studies | Treating latent autoimmune diabetes of adults with farnesoid X receptor agonists to activate intestinal receptors |
| WO2017049176A1 (en) * | 2015-09-16 | 2017-03-23 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| EP3350165B1 (en) | 2015-09-16 | 2023-07-26 | Organovo, Inc. | Farnesoid x receptor agonists and uses thereof |
| EP3350166A4 (en) * | 2015-09-16 | 2019-05-01 | Metacrine, Inc. | FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF |
| WO2018170173A1 (en) * | 2017-03-15 | 2018-09-20 | Metacrine, Inc. | Farnesoid x receptor agonists and uses thereof |
| AU2018236275B2 (en) * | 2017-03-15 | 2022-05-12 | Eli Lilly And Company | Farnesoid X receptor agonists and uses thereof |
| DK3596053T3 (da) * | 2017-03-15 | 2023-09-25 | Organovo Inc | Farnesoid-x-receptoragonister og anvendelser deraf |
| EP3852748B1 (en) * | 2018-09-18 | 2025-09-03 | Eli Lilly and Company | Farnesoid x receptor agonists and uses thereof |
-
2021
- 2021-03-17 KR KR1020227036071A patent/KR20220154801A/ko active Pending
- 2021-03-17 CN CN202511190792.8A patent/CN120732855A/zh active Pending
- 2021-03-17 JP JP2022555913A patent/JP7851856B2/ja active Active
- 2021-03-17 US US17/906,580 patent/US20230131804A1/en active Pending
- 2021-03-17 MX MX2022011579A patent/MX2022011579A/es unknown
- 2021-03-17 CN CN202180036461.2A patent/CN115666559A/zh active Pending
- 2021-03-17 TW TW110109622A patent/TWI895384B/zh active
- 2021-03-17 IL IL296539A patent/IL296539A/en unknown
- 2021-03-17 CN CN202511190799.XA patent/CN120732856A/zh active Pending
- 2021-03-17 BR BR112022018651A patent/BR112022018651A2/pt unknown
- 2021-03-17 EP EP21772019.2A patent/EP4121048A4/en active Pending
- 2021-03-17 CN CN202511190786.2A patent/CN120732854A/zh active Pending
- 2021-03-17 CA CA3172205A patent/CA3172205A1/en active Pending
- 2021-03-17 WO PCT/US2021/022786 patent/WO2021188688A1/en not_active Ceased
- 2021-03-17 AU AU2021240001A patent/AU2021240001A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL296539A (en) | 2022-11-01 |
| CN120732854A (zh) | 2025-10-03 |
| EP4121048A4 (en) | 2024-06-12 |
| US20230131804A1 (en) | 2023-04-27 |
| EP4121048A1 (en) | 2023-01-25 |
| JP7851856B2 (ja) | 2026-04-27 |
| JP2023518397A (ja) | 2023-05-01 |
| KR20220154801A (ko) | 2022-11-22 |
| BR112022018651A2 (pt) | 2022-11-29 |
| AU2021240001A1 (en) | 2022-10-13 |
| CN115666559A (zh) | 2023-01-31 |
| WO2021188688A1 (en) | 2021-09-23 |
| TWI895384B (zh) | 2025-09-01 |
| CN120732855A (zh) | 2025-10-03 |
| CN120732856A (zh) | 2025-10-03 |
| TW202143961A (zh) | 2021-12-01 |
| MX2022011579A (es) | 2022-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220323414A1 (en) | Farnesoid x receptor agonists for the treatment of disease | |
| US20230131804A1 (en) | Farnesoid x receptor agonists for the treatment of disease | |
| Hu et al. | Pipeline of new drug treatment for non-alcoholic fatty liver disease/metabolic dysfunction-associated steatotic liver disease | |
| JP7369033B2 (ja) | 線維症の治療 | |
| US11197870B2 (en) | Treatment for hepatic fibrosis | |
| US20120071451A1 (en) | Method of treating nonalcoholic steatohepatitis with elevated doses of ursodeoxycholic acid | |
| JP2017528431A (ja) | 器官再生のための内因性回腸ブレーキホルモン経路の活性化、並びに関連する組成物、治療方法、診断、及び制御システム | |
| KR20170049606A (ko) | 간 질환을 치료하기 위한 오메가-3 지방산과 sglt-2 억제제의 조합 | |
| TW202114672A (zh) | 使用fxr促效劑的肝臟疾病之組合治療 | |
| Ezhilarasan | Mechanism of semaglutide in MASLD treatment: where is the master key? | |
| Sinakos et al. | Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis | |
| WO2021188690A1 (en) | Farnesoid x receptor agonists for the treatment of disease | |
| HK40131843A (en) | Farnesoid x receptor agonists for the treatment of diseases | |
| HK40131844A (en) | Farnesoid x receptor agonists for the treatment of disease | |
| Maroni¹ et al. | The pathophysiology of gut-liver | |
| US20250332176A1 (en) | Treatment for fibrosis and inhibition of fibrosis | |
| KR102785819B1 (ko) | Lcn2 단백질 또는 그를 코딩하는 폴리뉴클레오티드를 유효성분으로 포함하는 발기부전 예방 또는 치료용 약학 조성물 | |
| Sumida et al. | An eBook on Diabetes | |
| Magdaleno et al. | Animal Models When Examining the Gut-Liver Axis | |
| HK1237676A1 (en) | Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems | |
| CN110062634A (zh) | 非酒精性脂肪肝病患者中纤维化的抑制 | |
| Lesley et al. | Present and future challenges in Type 2 diabetes | |
| HK1197541A (en) | Oral formulations mimetic of roux-en-y gastric bypass actions on the ileal brake; compositions, methods of treatment, diagnostics and systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and t2d |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250307 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250307 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250307 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250307 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250307 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250307 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250324 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250324 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250324 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250324 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20250429 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250429 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250512 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250710 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260227 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260227 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260520 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260728 |